Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 4,516 matching trials from the live ClinicalTrials.gov search.
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib
Drug
Lead sponsor
Alfasigma S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
2,731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
72
States / cities
Huntsville, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more
Conditions
Alzheimer Disease
Interventions
Simufilam
Drug
Lead sponsor
Cassava Sciences, Inc.
Industry
Eligibility
51 Years to 89 Years
Enrollment
1,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
107
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 94 more
Conditions
Secondary Hypogonadism
Interventions
Androxal 12.5 mg/25 mg, Placebo Capsules, AndroGel 1.62%, Placebo Gel
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Birmingham, Alabama • Mobile, Alabama • Evanston, Illinois + 6 more
Conditions
Sarcoma
Interventions
semaxanib, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
207
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 163 more
Conditions
Common Cold
Interventions
Acetaminophen 650mg+Dextromethorphan 20mg+Phenylephrine 10mg, Acetaminophen 325mg+Dextromethorphan 10mg+Phenylephrine 5mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
21 Years to 45 Years · Male only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Glioblastoma, Gliosarcoma
Interventions
Lomustine, Magnetic Resonance Imaging, Photon Beam Radiation Therapy, Questionnaire Administration, Temozolomide
Drug · Procedure · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years to 70 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
418
States / cities
Fairbanks, Alaska • Fayetteville, Arkansas • Little Rock, Arkansas + 304 more
Conditions
Adrenocortical Carcinoma
Interventions
suramin, therapeutic hydrocortisone
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
65
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
Conditions
Epilepsy
Interventions
perampanel
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
1 Month to 4 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
17
States / cities
Los Angeles, California • Gulf Breeze, Florida • Loxahatchee Groves, Florida + 13 more
Conditions
Chronic Myelogenous Leukemia - Chronic Phase
Interventions
asciminib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
80
States / cities
Birmingham, Alabama • Anchorage, Alaska • Scottsdale, Arizona + 71 more
Conditions
Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions
Pumitamig, Imzokitug, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
12
States / cities
Washington D.C., District of Columbia • Athens, Georgia • Lexington, Kentucky + 8 more
Conditions
Leukemia, Myeloid, Chronic, Leukemia, Lymphocytic, Acute, L2
Interventions
Dasatinib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
30
States / cities
Corona, California • Aurora, Colorado • Colorado Springs, Colorado + 27 more
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Removable Partial Denture Abutments Restored With Monolithic Zirconia Crowns

NCT03283709
Conditions
Crowns, Denture
Interventions
Full-contour monolithic zirconia abutment crowns, Conventional abutment crowns
Device
Lead sponsor
Hiroko Nagaoka
Other
Eligibility
25 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Active, not recruiting Not applicable Interventional

SyncAV Post-Market Trial

NCT04100148
Conditions
Congestive Heart Failure
Interventions
SyncAV programmed ON, Fixed AV delay
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
30
States / cities
Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 25 more
Conditions
Hereditary Spastic Paraplegia
Interventions
transcutaneous spinal cord stimulation
Device
Lead sponsor
Rahul Sachdeva
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Placebo, Permitted DMARDs
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
619 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
156
States / cities
Birmingham, Alabama • Montgomery, Alabama • Lake Havasu City, Arizona + 135 more
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin (SAR439954), Placebo, Metformin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
67
States / cities
Birmingham, Alabama • Phoenix, Arizona • Canoga Park, California + 50 more
Conditions
Early Alzheimer's Disease
Interventions
Lecanemab IV, Placebo, Lecanemab SC
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
112
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 82 more
Conditions
Ovarian Cancer, Ovarian Neoplasm
Interventions
Veliparib, Paclitaxel, Carboplatin, Placebo to Veliparib
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
135
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 101 more
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Bilateral Breast Carcinoma, Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8
Interventions
Intraoperative Imaging, Lumpectomy
Procedure · Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Chicago, Illinois • Lexington, Kentucky • St Louis, Missouri + 1 more
Conditions
Fatigue
Interventions
armodafinil 150 mg, Placebo, armodafinil 250 mg
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
365
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 254 more
Conditions
Generalized Myasthenia Gravis
Interventions
Rozanolixizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 7 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)

NCT04134767
Conditions
Substance Use, HIV Infections, HCV Infection, Sexually Transmitted Infections (Not HIV or Hepatitis), Overdose, Drug, Opioid Use
Interventions
Health Linkage, Overdose Education
Behavioral
Lead sponsor
April M Young
Other
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Hypertension, Stroke
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
30 Years and older
Enrollment
1,244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
30
States / cities
Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 23 more
Conditions
Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma, Papillary Squamous Cell Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Fludeoxyglucose F-18, Image Guided Radiation Therapy, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
493
States / cities
Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 348 more